Institution Directory

Clinical trials at UPMC (University of Pittsburgh)

Sites in Pittsburgh, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1595

Shown on this page

Current sort

Live official records

Conditions: Fabry Disease
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 9,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2034
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more

Conditions: Burkitt Lymphoma, Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Lumbar Puncture, Pidnarulex, Positron Emission Tomography; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 8
States / cities: Irvine, California • Orange, California • Fairway, Kansas + 5 more

Conditions: Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
Interventions: Therapeutic Hypothermia; Device
Lead sponsor: University of Michigan; Other
Eligibility: 2 Days to 17 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 44 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 225
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 179 more

Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cemiplimab, Cisplatin, Computed Tomography, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Salvage Surgery; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 113
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 83 more

Conditions: Interstitial Lung Diseases
Interventions: Nerandomilast, Placebo matching nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 25 more

Conditions: Systemic Lupus Erythematosus
Interventions: Ianalumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 22
States / cities: Anniston, Alabama • Burbank, California • La Jolla, California + 19 more

Conditions: Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Tumor
Interventions: Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Survey Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more

Conditions: mCRPC
Interventions: Talazoparib with enzalutamide, Placebo with enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 132
States / cities: Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 93 more

Conditions: Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC)
Interventions: Darlifarnib, Cabozantinib, Adagrasib; Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more

Conditions: Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Fludeoxyglucose F-18, Mosunetuzumab, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 36
States / cities: Duarte, California • Aventura, Florida • Coral Gables, Florida + 31 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 215
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more

About this UPMC (University of Pittsburgh) institution page

What this page lists: ClinicalTrials.gov records that list UPMC (University of Pittsburgh) in Pittsburgh, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UPMC (University of Pittsburgh)

Filter and sort this campus

Live official records

Fabry Disease Registry & Pregnancy Sub-registry

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

About this UPMC (University of Pittsburgh) institution page